Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Quest Diagnostics (DGX) Form 144 filing shows an insider planned sale and recent dispositions. The notice reports an intended sale of 227 common shares through Fidelity Brokerage with an aggregate market value of $42,706 and an approximate sale date of 09/26/2025. The 227 shares were acquired under an option (granted 02/19/2018) and will be paid in cash. The filer also reported two recent sales in the prior three months: 28,288 shares on 09/23/2025 for $5,293,312.79 and 175 shares on 09/24/2025 for $32,729.03. The filer attests not to possess undisclosed material adverse information.
Michael E. Prevoznik, Senior Vice President & General Counsel of Quest Diagnostics (DGX), reported option exercises and subsequent sales executed under a Rule 10b5-1 plan. On 09/23/2025 he exercised 28,288 non-qualified options at an exercise price of $103.57 and sold those 28,288 shares at a weighted-average price of $187.1222, leaving 38,117 shares beneficially owned after that transaction. On 09/24/2025 he exercised 175 options at $103.57 and sold 175 shares at a weighted-average price of $187.023, with total beneficial ownership remaining 38,117 shares. He also holds 5,691 shares indirectly in company retirement plans and retains outstanding options covering 28,288 and 175 shares that vested in installments beginning February 19, 2019.
Form 144 filed for Quest Diagnostics (DGX) reports a proposed sale of common stock and recent related transactions. The notice shows an intended sale of 175 shares through Fidelity Brokerage Services with an aggregate market value of $32,729 and an approximate sale date of 09/24/2025 on the NYSE. The 175 shares were acquired by option exercise on 09/24/2025 with cash payment. The filing also discloses a separate sale on 09/23/2025 by Michael Prevoznik of 28,288 common shares for gross proceeds of $5,293,312.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 procedures.
Quest Diagnostics (DGX) filed a Form 144 notifying a proposed sale of 28,288 common shares through Fidelity Brokerage Services LLC on 09/23/2025 on the NYSE. The filing lists an aggregate market value of $5,293,313.43 and reports 111,823,441 shares outstanding, indicating the sale represents a very small fraction of total shares. The shares are reported as acquired under an option granted 02/19/2018 with acquisition and payment dated 09/23/2025 and payment in cash. The filer certifies they are unaware of undisclosed material adverse information and the notice contains the standard attestation language required by Rule 144.
Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported an insider sale under a Rule 10b5-1 plan. On 08/21/2025 he disposed of 1,975 shares of Quest Diagnostics common stock at $185 per share. Following the transaction, he beneficially owned 15,269 shares, held directly. The filing indicates the sale was executed pursuant to an established 10b5-1 trading plan and the Form 4 was signed by an attorney-in-fact on 08/25/2025. No derivative transactions or other securities were reported in this filing.
Quest Diagnostics (DGX) officer Patrick Plewman reported option exercise and a contemporaneous sale on 08/19/2025. He exercised 4,532 non-qualified stock options at an exercise price of $112.17 per share, resulting in ownership of 4,532 underlying shares. Immediately thereafter he sold 4,532 shares at $183.00 per share. After these transactions his beneficial ownership in the issuer is reported as 17,244 shares. The filings state the exercise and sale were executed pursuant to a Rule 10b5-1 sales plan and that the options vested in three annual installments between 2021 and 2023.
Quest Diagnostics insider Thomas P. Plewman filed a Form 144 disclosing a proposed sale of 1,975 common shares (approximate aggregate market value $365,375) to be sold via Fidelity Brokerage Services on the NYSE on 08/21/2025. The shares were acquired on 02/18/2022 upon restricted stock vesting and were received as compensation. The filer also reported three recent sales in August 2025 totaling 12,042 shares for gross proceeds of $2,153,481 (sales on 08/06/2025, 08/15/2025, and 08/19/2025). The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported a sale of 1,975 shares of Quest Diagnostics common stock on 08/15/2025 at a price of $180 per share. Following the reported sale, Mr. Plewman beneficially owns 17,244 shares, held directly. The filing notes the sale was effected pursuant to a Rule 10b5-1 sales plan. The Form 4 was executed on behalf of Mr. Plewman by an attorney-in-fact on 08/19/2025.
Form 144 notice for Quest Diagnostics (DGX) shows a proposed sale of 4,532 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $829,356.00 and an approximate sale date of 08/19/2025. The shares were acquired on 08/19/2025 under options originally granted 02/18/2020 and payment is indicated as cash. The filer also reported two recent sales by the same person: 5,535 shares on 08/06/2025 for $968,625.00 and 1,975 shares on 08/15/2025 for $355,499.90. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Quest Diagnostics (DGX) Form 144 notice shows a proposed sale of 72 shares of common stock through Fidelity Brokerage (approximate aggregate market value $12,960.00) with an approximate date of sale of 08/15/2025. The filer reports prior acquisitions via the company's ESPP: 12 shares acquired 01/31/2022 and 60 shares acquired 07/19/2024, both paid in cash. The filing also discloses a recent sale by Thomas P. Plewman of 5,535 shares on 08/06/2025 for gross proceeds of $968,625.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references trading-plan/Rule 10b5-1 provisions but does not state a plan adoption date.